SYKESVILLE, MD – April 24, 2017 – Noble Life Sciences, a full service, GLP (Good Laboratory Practice)-compliant and non-GLP preclinical contract research organization (CRO), today announced that its Board of Directors has appointed Srujana Cherukuri as Chief Executive Officer (CEO) effective immediately. The board also announced that Dr. Cherukuri is now majority owner of Noble Life Sciences.
"With the acquisition of Spring Valley Laboratories, Noble Life Sciences has grown from a contract research organization offering in vivo drug services in small animals to a full service CRO offering services for the development of drugs, devices, and vaccines in a range of large and small animals," said Ken Carter, Chairman of the Board. "Because the integration of Spring Valley Laboratories is complete, now is the right time to appoint a CEO who will continue Noble’s growth. Dr. Cherukuri was key to the successful integration process, we are enthusiastic about her vision to ensure Noble’s continued growth and future success.”
Dr. Cherukuri has served in multiple roles at Noble including Chief Operations Officer, Chief Scientific Officer, Vice President of Product Development and Operations, and Director of Scientific Affairs. She led the consolidation of Noble operations at the Spring Valley Laboratories site. Prior to joining Noble, Dr. Cherukuri held positions at the Cleveland Clinic Foundation, National Cancer Institute and University of Maryland where she led projects focused on understanding the basic biology and mechanistic actions in cancer cells. Dr. Cherukuri completed her PhD in biology at Cleveland State University.
“I’m incredibly excited about Noble’s future,” added Dr. Cherukuri. “We have a remarkable team of talented scientists and a collaborative approach to our interactions with our clients. As we add capabilities and deepen our expertise, our mission remains unchanged – to help our clients expedite their development of new drugs, devices, and vaccines.”
About Noble Life Sciences
Noble Life Sciences is a full-service preclinical contract research organization offering GLP and non-GLP services, in both large and small animals, for the development of drugs, vaccines, and medical devices. Preclinical development services include PK and PD studies; biodistribution studies; immunization and immunogenicity testing; early safety assessments; reproductive and developmental toxicity testing; surgical services; medical device protocol development and testing; analytical and imaging services; and preclinical formulation development. Our services also include the derivation and maintenance of animal breeding colonies, animal housing and husbandry, the development of disease and animal models, and the production of custom antibodies and are backed by AAALAC accreditation, OLAW assurance, a USDA license and over 50 years of experience. For more information about Noble Life Sciences, visit www.noblelifesci.com.
"With the acquisition of Spring Valley Laboratories, Noble Life Sciences has grown from a contract research organization offering in vivo drug services in small animals to a full service CRO offering services for the development of drugs, devices, and vaccines in a range of large and small animals," said Ken Carter, Chairman of the Board. "Because the integration of Spring Valley Laboratories is complete, now is the right time to appoint a CEO who will continue Noble’s growth. Dr. Cherukuri was key to the successful integration process, we are enthusiastic about her vision to ensure Noble’s continued growth and future success.”
Dr. Cherukuri has served in multiple roles at Noble including Chief Operations Officer, Chief Scientific Officer, Vice President of Product Development and Operations, and Director of Scientific Affairs. She led the consolidation of Noble operations at the Spring Valley Laboratories site. Prior to joining Noble, Dr. Cherukuri held positions at the Cleveland Clinic Foundation, National Cancer Institute and University of Maryland where she led projects focused on understanding the basic biology and mechanistic actions in cancer cells. Dr. Cherukuri completed her PhD in biology at Cleveland State University.
“I’m incredibly excited about Noble’s future,” added Dr. Cherukuri. “We have a remarkable team of talented scientists and a collaborative approach to our interactions with our clients. As we add capabilities and deepen our expertise, our mission remains unchanged – to help our clients expedite their development of new drugs, devices, and vaccines.”
About Noble Life Sciences
Noble Life Sciences is a full-service preclinical contract research organization offering GLP and non-GLP services, in both large and small animals, for the development of drugs, vaccines, and medical devices. Preclinical development services include PK and PD studies; biodistribution studies; immunization and immunogenicity testing; early safety assessments; reproductive and developmental toxicity testing; surgical services; medical device protocol development and testing; analytical and imaging services; and preclinical formulation development. Our services also include the derivation and maintenance of animal breeding colonies, animal housing and husbandry, the development of disease and animal models, and the production of custom antibodies and are backed by AAALAC accreditation, OLAW assurance, a USDA license and over 50 years of experience. For more information about Noble Life Sciences, visit www.noblelifesci.com.
